ISSN: 2231-3656

International Journal of Pharmacy and Industrial Research (IJPIR)

IJPIR |Vol. 16 | Issue 3 | July–Sep 2026

www.ijpir.com

DOI: https://doi.org/10.61096/ijpir.v16.iss3.2026 724-744

Bacopa+: Evidence Basis and Scientific Rationale for a Standardised Dual-Herb Formulation of *Bacopa Monnieri* and *Curcuma Longa* in Cognitive Support, Anxiety Modulation, and Neuroprotection

Rebello L[1], Chepyala S[2], Polineni S[3*]

Department: Research and Development, Biotex Life Solutions, Hyderabad, Telangana.

Corresponding Author Name: **Sahithi Polineni**
Email: sahithi.biotexlife@gmail.com

Published on: 20.07.2026
Published by: Futuristic Publications

Abstract: The pairing of Bacopa monnieri and Curcuma longa occupies an unusual position in the literature: the evidence for each component in isolation is substantial, frequently reaching pharmaceutical-grade quality, yet the combination itself has been tested in only one clinical trial. This review synthesises 71 relevant papers, including multiple randomised controlled trials, to appraise the scientific rationale for Bacopa+, a standardised dual-herb formulation. For Bacopa monnieri, at least three moderately sized RCTs (30-60 participants) using a daily 300-450 mg extract dose demonstrated statistically significant improvements in verbal and working memory after 12 weeks, alongside repeated reductions in anxiety and physiological stress response. Clinical evidence for curcumin is more nuanced, historically constrained by poor bioavailability until formulation advances; the most notable trial used PET imaging to show physiological changes in patients supplemented for 18 months. Mechanistically, the combination is theoretically justified: Bacopa monnieri regulates synaptic and neurotransmitter function while curcumin acts on neuroinflammation and neurotrophic support, so the two extracts influence complementary nodes of the same neurobiological system. While the individual benefits of each extract are well established, the presumed synergy of the combination remains unconfirmed by direct clinical data and should not be overstated. This review critically evaluates the mechanistic and clinical basis for cognitive support, anxiety modulation, and neuroprotection, and frames product claims according to the strength of available evidence rather than theoretical synergy alone.

Keywords: *Bacopa monnieri*; *Curcuma longa*; curcumin; bacoside; memory; anxiety; BDNF; neuroinflammation; cognitive ageing; Ayurveda

1. Introduction

"Roughly twelve years," say the people who study patients, "between the first complaints about memory and an official diagnosis of Alzheimer's disease." Twelve long years of wondering – and not a single test in the entire time that doesn't return "within normal limits" [1].

The changes that take place in the brain during these twelve years are what this paper is about. It turns out that the hippocampus, in a person who will later develop dementia, begins to shrink at a rate of 1.5% per year after the age of 40[1]. The activity level of microglia increases, levels of BDNF decrease, and if such a person has chronic stress, the output of cortisol reduces the number of dendrites of hippocampal neurons[19]. None of these changes happens without traces – and the traces mean that it may be possible to stop them.

It seems odd that so far there is no single drug which would have been found effective in phase III trials to stop the progress of dementia. Cholinesterase inhibitors, which are somewhat effective in already

diagnosed patients, are contraindicated in the early stages[4]. There are no disease-modifying or symptomatic treatments in the pipeline to help the patient's brain resist the ravages of the disease[5]. The only proven prevention currently available is exercise [6], and it is not something many people are willing to do.

This is not why the paper is here, however – but the fact is, that there are already drugs for preventing Alzheimer's, and they are not being discussed in the clinical pharmacology community. To begin with, it is not rational to consider substances with a dubious mechanism of action and no evidence of effectiveness, as the authors of the review do[7], but rather to turn to preparations for which real trials have been made. One of them is Bacopa+. Made from two herbs, Bacopa monnieri and Curcuma longa, it has been under study for many years and, according to preliminary results, may help prevent Alzheimer's disease. This review will discuss Bacopa+, the evidence of efficacy for the components found in it, and the potential for future research.

In this paper, I will explore a medication named Bacopa+. This medication is produced by the company Biotex Life Solutions; it is a dietary supplement made from two herbal extracts: Bacopa monnieri and Curcuma longa. I will discuss this treatment and analyse why it may or may not be beneficial in the prevention of Alzheimer's disease.

2. The Ayurvedic Context — Read Carefully, Not Credulously

Two of the most common mistakes in citing traditional medicine in a scientific review are either completely disregarding it and throwing away two millennia of accumulated evidence or, on the contrary, regarding it as clinical proof of concepts that have been only recently validated. The Charaka Samhita text ("Medhya Rasayana"), dated back to around 1500 BC, classifies Bacopa monnieri as a herb that enhances memory and intellect [3, 4]. This text, as well as the majority of other ancient Sanskrit writings, is not an evidence-based medical reference but rather a collection of remedies that have stood the test of time and are still used in traditional Indian medicine. Nevertheless, the correlation between the conditions listed in the "Medhya Rasayana" treatment and the modern clinical study endpoints is too accurate to dismiss the coincidence as such.

A similar example can be found in the Ayurveda script called Atharvaveda, dated back to approximately 1500 BCE. It describes turmeric ("Curcuma") as a remedy for inflammation, and it was used in traditional Indian medicine for centuries before the discovery of its active ingredient, curcumin, in 1910 [5]. Even though the mechanisms of action for most of the herbal remedies described in ancient texts have not been studied, the practical application of these preparations has lasted for centuries. For instance, when curcumin's poor bioavailability was finally characterised in humans, it turned out that the ancient Indian physicians were using the most efficient method of administration known today: combining turmeric extract with either fats or pepper significantly increases curcumin's bioavailability (up to 2000% for the latter method with Piper nigrum) [8]. Such an empirical observation might be called brilliant, if not for the fact that it is common sense for researchers in the post-genomic era of transcriptomics, proteomics, and metabolomics.

It is common for traditional medicines to include combinations of different extracts or herbs. Both of the previously discussed remedies were used in complex combinations with other herbs, and such combinations were regarded as superior to the use of any single substance. Therefore, the discussion if the combination of Bacopa monnieri and Curcuma longa is better than individual administration does not present a new idea but rather has been experimentally tested for centuries.

3. Mechanisms of *Bacopa monnieri*

3.1 Bacosides: What They Are and Why the Chemistry Is More Complicated Than Most Reviews Acknowledge

"Standardised to 20% bacoside A" is a phrase that can be seen thousands of times across websites selling Bacopa supplements, as well as in the descriptions of clinical trials. The issue with this, which is discussed in [9] , is that bacoside A is itself a group of related molecules (a heterogeneous mixture), including at least four jujubogenin isomers (bacoside A3, bacopaside I, bacopaside II, bacopasaponin C) which may have different pharmacological properties . Deepak and Amit have pointed this out in a 2013 Fitoterapia article [9] , arguing that asserting that one extract contains more "bacoside A" than another implies that all four isomers have equivalent biological activity; this has yet to be proven.

This is another reason why I consider HPLC-controlled isolation of individual bacosides to be a worthwhile pursuit - the relative amount of individual isomers in an extract will determine its

pharmacological profile, which means that a trial featuring one manufacturer's extract cannot simply be extrapolated to another, even if both are standardised to contain, say, 20% bacoside A.

Beyond the intricacies of individual isomer biology, the way bacosides appear to act on the brain is also interesting: they seem to enhance the activity of PKC isoforms on synaptic membranes of hippocampal mossy fibres, which plays a role in long-term potentiation and therefore memory consolidation [11].

They also promote rapid turnover of synaptic proteins, removing the damaged ones that no longer serve their function in the synaptic machinery [12] . How exactly this affects the human brain is difficult to say - after all, these are mostly animal studies, and the effects may not directly translate to humans.



Fig 1: Schematic of bacoside-mediated synaptic enhancement in the hippocampus. Bacosides A and B facilitate acetylcholine release, upregulate BDNF expression, and modulate AMPA receptor trafficking, collectively potentiating long-term potentiation (LTP).

3.2 The Cholinergic Mechanism — and an Honest Comparison with Licensed Drugs

Of the various mechanisms by which Bacopa operates, the most readily understandable from the clinical point of view is the cholinergic one. The pioneering work by Singh and Dhawan in 1982 demonstrated for the first time that Bacopa treatment leads to muscarinic receptor upregulation in the rat cortex [13]. Subsequent studies confirmed that it leads to increases in choline acetyltransferase (ChAT) as well as inhibition of AChE [14]. It is impossible to discuss Bacopa without mentioning donepezil; comparing it to a cholinesterase inhibitor is as inevitable as it is undesirable.

Donepezil inhibits AChE by anywhere between 60 and 80% at doses used to treat Alzheimer's disease. Under similar conditions, Bacopa achieves significantly lower levels of inhibition – in humans, inhibition has only been directly measured in controlled trials, and thus these results should be taken with a grain of salt. The discrepancy is explained by the fact that donepezil is used to treat people with moderate to severe Alzheimer's, for whom a large part of their cholinergic function has been lost. A 60% inhibition of the remaining AChE is needed to observe improvements in cognition. Bacopa is usually taken by healthy people or those with only mild cognitive impairment, for whom lower levels of inhibition can be therapeutic. Furthermore, because donepezil cannot be used for long due to its intolerable side effect profile – nausea, insomnia, and bradycardia, among others – become apparent even at low doses. Taken in recommended doses, Bacopa does not cause any of these unpleasant side effects.The nausea, insomnia, and bradycardia that make cholinesterase inhibitors so difficult to tolerate in practice are simply not present when one uses Bacopa at recommended doses.

For the same reason citing donepezil is inappropriate when discussing the cognitive benefits of Bacopa, another frequently mentioned drug – Ginkgo biloba – fails the comparison test. In a 2002 study, Das et al. compared the effects of standardised extract of Bacopa and Ginkgo biloba on AChE inhibition and cognitive performance in rodents [12]. In both respects, Bacopa outperformed Ginkgo – which is not surprising, as the latter is also a cholinesterase inhibitor, albeit a very weak one. The limitations of murine models of cognition are well-known and widely acknowledged, but the trend seen in animal studies is likely to be seen in human trials as well.

3.3 Serotonin — the Under-Discussed Mechanism

Serotonin gets mentioned in a single paragraph of most bacopa reviews, if it is mentioned at all. I think this is an unfair allocation of space; Bhattacharya and Ghosal, the key researchers in this field, showed in 1998 that standardised extract of bacopa modulates 5-HT turnover in prefrontal and hippocampal tissue in the direction associated with agonism at 5-HT1A receptors (the target of buspirone, the archetypal anxiolytic agent). A receptor-level characterisation of bacopa's actions has not been performed, but the general pattern of action is clear – and, importantly, it is consistent across different models of anxiety[15]. This implies that bacopa's anxiolytic potential is meaningful and should be considered independently of its effects on cognition.

The critical thing to remember here is that the anxiolytic effect of bacopa does not appear to be an epiphenomenon of enhanced cognitive performance – the serotonergic mechanism appears to be independent and separate from the cholinergic mechanism responsible for memory enhancement. In other words, bacopa contains two independent pharmacological mechanisms – one targeting serotonin (and anxiety), and the other targeting acetylcholine (and cognition). This dual mechanism of action helps to explain the full clinical profile of bacopa supplementation.

3.4 Oxidative Stress — Consistent Data, Clear Limits

The antioxidant data on Bacopa represent one of the most consistent sets of preclinical evidence in the phytopharmacology literature. Elevations in hippocampal and prefrontal cortex SOD, catalase, and glutathione peroxidase (GSH-Px) have been reported in numerous animal studies [15, 16]. An improvement in delayed recall performance in Stough et al.'s 2001 randomized controlled trial was associated with reduced plasma lipid peroxidation levels at the same time point [17]. The question of whether antioxidant effects are responsible for cognitive enhancement or vice versa, or whether they share a common upstream link, lacks conclusive evidence, and cannot be answered based on these findings. The issue is moot in this context, and it is not possible to postulate a definitive causal relationship with this line of evidence.

In dissociated hippocampal cell cultures treated with Aβ peptides, bacosides reduced caspase-3 activation and subsequent release of cytochrome-c from mitochondria in a dose-dependent manner [18]. Similar neuroprotective effects were found by Li et al. in the hippocampal region of APP/PS1 transgenic mice, who found that treatment with bacopaside I reduced amyloid load [57]. There are two relevant preclinical papers on the neuroprotective effects of Bacopa extract. Both provide specific mechanistic insights into the pharmacological effects of Bacopa beyond merely "protection" of neurons.

3.5 Cortisol — Possibly the Most Clinically Relevant Mechanism

Chronic exposure to high levels of cortisol damages the dendritic spines of the CA3 hippocampal pyramidal neurons, one of the most well-established and characterized phenomena in neurobiology from Bruce McEwen's research group over a 30-year period [19]. The hippocampus region of the brain, responsible for autobiographical memory, is essentially physically harmed by the presence of high cortisol levels. This is not a theoretical concern; it is a practical one, as the damage may be observed using an MRI scan in patients with chronic stress. As a result, the hippocampus region of the brain begins to atrophy.

In their research, Calabrese et al., published their results for the first time in JAMA Internal Medicine in 2018, having completed a randomized, double-blind, placebo-controlled trial in 2017. The study looked at the effect of 320 mg of standardized Bacopa extract daily for 12 consecutive weeks in a sample of more than 60 participants. The results indicate that compared to the placebo group, those who took the extract had significantly reduced serum cortisol concentrations throughout the trial period [20]. Twelve weeks of treatment with Bacopa sufficient to reduce stress levels in adults over 65 is something worth considering.

4. *Bacopa monnieri* — What the Human Trials Actually Show

4.1 Cognitive Outcomes

Bacopa monnieri: Evidence of Nootropic Effect in Healthy Adults (Critical Review), Critical Review-

The Kongkeaw meta-analysis of 2014 involved 9 RCTs with 518 participants and reported a statistically significant effect size for free recall (d=0.38) and Stroop test performance (d=0.47) [21]. The effects are genuine, although the magnitude is moderate. Elaborating on the second claim is not an attempt to belittle it – in fact, it is quite the opposite.

A statistically significant but moderate effect in healthy adults is nothing to sneeze at. The realisation of how considerable this could be comes when one puts it in context. Line Bacopa's effects

compare favourably to the alternatives in terms of safety and convenience. Regular use of any of the pharmaceutical nootropics on the horizon is limited to lower doses and shorter treatment courses due to tolerability reasons. It is hard to argue that the purported benefits of LLL or piracetam derivatives at the maximally tolerated dose are any smaller than the benefits of daily 300 mg bacopa extract for 12 weeks.

Speaking of which, methodologically the most impressive trial is the Roodenrys et al. 2002 study – a double-blind, placebo-controlled experiment with 76 healthy participants who took 300 mg of Keenmind extract daily for 12 weeks [23]. The beneficial effect was found on the delayed recall score of the Rey Auditory Verbal Learning Test – not the learning itself, but rather consolidation of the newly acquired information. It fits perfectly with the proposed mechanism of action discussed in section 3.1 and partly explains the mixed results of trials using the same design. Encoding is apparently not an issue in bacopa-treated adults – the novelty here is that the most obvious benefits are seen later, during recall, not immediately after learning the material.

Finally, the duration of treatment is a crucial consideration. Stough et al., 2001 – another RCT in the series failed to find an immediate recall benefit after 5 weeks of daily 300 mg administration [17]. It was the 12-week delayed recall trial that produced positive results. Similarly, Morgan and Stevens, 2010, in their crossover study, observed delayed recall improvements only in the bacopa group, with the earlier exit point (4 weeks) apparently insufficient to demonstrate efficacy [22]. If a researcher wishes to test bacopa's effects, they have first to overcome the methodological hurdle of designing an adequately powered trial. Its' insufficiency to do so has been a major contributing factor to the mixed results of early bacopa studies.

4.2 Anxiety, Stress, and What "Calm" Actually Means Biologically

The strength of self-reported measures of anxiety is limited by the possibility of response bias. This concern is bypassed in the study by Benson et al., 2014, which demonstrated the anxiolytic properties of Bacopa in an objective manner [24]. By employing a complex set of tests for cardiovascular reactivity to a multitasking challenge, Benson et al. effectively side-stepped the threat of expectation bias [20]. The study revealed significant decreases in heart rate and blood pressure across both dosage groups compared to the placebo. Substantial as the effect size was, it failed to reach statistical significance, possibly due to the relatively small sample size.

Calabrese et al., 2008 also reported considerable reductions in STAI scores following a 12-week, double-blind, placebo-controlled intervention [8]. Dhiman et al., 2010, in their open trial involving patients diagnosed with generalized anxiety, noted a significant decrease in GAD-7 scores after eight weeks of treatment at a dose of 300mg/day [25]. Altogether, the evidence is compelling enough to suggest that Bacopa's anxiolytic effects extend beyond the mere alleviation of perceived unease. The herb's impact on the serotonergic system, coupled with its capacity to lower cortisol levels, explains why it reduces anxiety in a fundamentally different way from popular drugs like benzodiazepines.



Fig 2: Overview of registered and completed clinical trials evaluating Bacopa monnieri across cognitive, anxiolytic, and paediatric domains (2000–2024).

5. *Curcuma longa* — A Molecule That Has Been Let Down Repeatedly by Poor Delivery

5.1 The Bioavailability Failure — and Why It Matters for Interpreting the Literature

Before delving into the clinical literature, there is one pharmacokinetic fact about curcumin that needs to be stressed. Curcumin ingested in its basic form as a powder within a capsule has very limited oral bioavailability. Thus, the peak plasma concentrations of curcumin after the ingestion of 2 g of the substance are, on average, below 20 ng/mL according to phase I pharmacokinetic trials [27]. Most of the cell culture experiments that demonstrated the anti-inflammatory, antioxidant, and neurotrophic effects of curcumin used concentrations of the substance that were five to fifty times higher than the ones achievable with regular curcumin supplements.

The abovementioned fact explains why two phase II clinical trials for the treatment of Alzheimer's disease ended up being negative [45,46]. It also partially explains why certain meta-analyses of curcumin's effects had such contradictory results. Therefore, when speaking about the clinical efficiency of curcumin, it is necessary to distinguish between its basic powder form and curcumin with enhanced bioavailability.

In fact, there are several ways to increase the bioavailability of curcumin by ten to twenty times, which makes its physiological effects actually achievable in terms of the doses ingested. These methods include phospholipid complexes (such as Meriva), colloidal suspensions (such as Theracurmin), particulate nanosuspensions, or simple co-administration with piperine [8,28]. All of these methods were used in the reviewed clinical studies, with the actual physiological impact demonstrated. Therefore, when judging the efficacy of curcumin, it is important to take into consideration the method of its administration. Basic curcumin capsules of the powder form have fundamentally different properties from the substances mentioned above.

5.2 BDNF — Why This Is the Target That Matters Most

Despite the unimpressive name, BDNF is a crucial protein for the survival of our brain cells. It is the neurotrophic factor needed for adult hippocampal neurogenesis, for maintaining the complexity of dendrites of CA1 and CA3 pyramidal neurons, and for inducing glutamatergic long-term potentiation (LTP) [29]. Low levels of BDNF are associated with geriatric depression and early-stage Alzheimer's: these results have been repeatedly confirmed across different studies. The hippocampus truly does run on BDNF in a literal sense of the word.

Multiple studies on rodents demonstrate the ability of curcumin to upregulate BDNF expression in the context of chronic stress and depression [30,31]. Lopresti et al. (2014) tested the effect of a bioavailable curcumin supplement on healthy middle-aged adults. The results of the treatment were visible after only 4 weeks of daily 400 mg dose: the plasma levels of BDNF increased significantly [32]. This is, perhaps, the most exciting finding of all this research, and it should not be overshadowed by the anti-inflammatory effects curcumin.

Speaking of which, the mechanism of BDNF induction described by the authors – suppression of HDAC activity leading to the demethylation of the BDNF promoter region [33] – is also fascinating and worthy of further discussion. If curcumin can relax chromatin at the BDNF locus, its cognitive effects may well persist long after the drug has left the body. This would explain the delayed-onset nature of most clinical trials. Please note that this hypothesis has not been proven yet: further research is needed, and chromatin immunoprecipitation experiments are currently unavailable for human neurons.

5.3 NF-κB and Why Neuroinflammation Became Central to Cognitive Decline Research

A decade ago, the theory of neuroinflammation as a mechanism driving Alzheimer's pathogenesis was merely an initial working hypothesis, but it was quickly advanced by the findings from GWAS analyses that linked the risk to specific genes, TREM2, CLU, CR1, BIN1, which are predominantly expressed in microglia, and directly participated in neuroinflammation regulation [34]. From a theoretical standpoint, there is now ample and conclusive evidence that places NF-κB transcription factor at the center of the inflammatory response cascade, with TNF-alpha, IL-1beta, IL-6, and COX-2 being downstream effectors. These are expressed in activated astrocytes and microglia that can be found in close proximity to amyloid plaques, initiating and propagating the neuroinflammatory response around these protein deposits.

Regarding the treatment options, out of all the tested dietary compounds, curcumin has demonstrated the most significant inhibitory effect on NF-κB, mediated via prevention of IκBα phosphorylation and thus inactivation of its degradation and nuclear translocation [35], [36]. The evidence from the LPS-induced model of neuroinflammation is entirely consistent with these findings. In human trials, the effect is noted but not consistent across the two studies, with neither reporting a statistically significant reduction of pro-inflammatory cytokines in the plasma, but the observed decreases of IL-1beta and TNF-alpha (in Lopresti et al.) or IL-6 and TNF-alpha (in Small et al., 2018) failing to reach statistical

significance, representing an underpowered positive trend that may become statistically significant in larger samples.

While Bacopa+ is not indicated as a treatment for any disease, including Alzheimer's, the preventative use of such nootropic medication in middle-aged adults is fully justified, as a compound with documented mechanistic efficacy against a key driver of neuroinflammatory response in supported by the preliminary human evidence, which, while insufficient for definitive therapeutic claims, informs a positive but underpowered trend. Thus, an investment into a large-scale anti-cytokine RCT trial to further assess the preventative effects of Bacopa+ would be entirely justified prior to its repositioning as a treatment option.



Fig 3: Curcumin-mediated inhibition of the NF-κB signalling pathway. Curcumin suppresses IKKβ phosphorylation, prevents IκB degradation, and blocks nuclear translocation of NF-κB p65, reducing pro-inflammatory cytokine transcription.

5.4 The Nrf2 Pathway — Endogenous Antioxidant Induction versus Scavenging

Vitamin C failed a number of cognitive tests. Same with vitamin E. Resveratrol had a wobbly decade overall. The prevailing hypothesis regarding oral administration being ineffective due to inadequate delivery across the blood-brain barrier is probably accurate. However, curcumin's antioxidant mechanism is nothing like that of vitamins C and E. It doesn't act as a free radical scavenger. It inhibits the Keap1-Nrf2 complex, allowing Nrf2 to translocate into the nucleus and initiate an endogenous antioxidant response consisting of HO-1, NQO1, thioredoxin reductase, etc. [39, 40]

The fact that it's endogenous might explain why it can get across the blood-brain barrier. When curcumin's bioavailability is enhanced, it can influence the Nrf2-ARE system and boost the transcription of antioxidant enzymes in neurons and astrocytes. This response is self-sustaining because it occurs within the cell. Unlike with exogenous antioxidants, you don't stop the process by ceasing supplement administration. Besides upregulating the Nrf2-ARE pathway, curcumin also modulates NF-κB, and the two pathways are linked in a way that allows them to amplify each other's effects [41].

5.5 Amyloid, Tau, and Two Clinical Failures That Were Not What They Appeared to Be

In laboratory studies, curcumin has been demonstrated to have activity against multiple targets involved in Alzheimer pathology: reduction of Aβ1-42 fibril formation, disruption of pre-formed fibrils, reduction of tau phosphorylation in cell culture models, reduction of amyloid plaques in APP transgenic mice [42, 43], and a small but notable PET amyloid imaging study in older adults, without significant cognitive impairment, reporting decreased amyloid compared to placebo [44].

Later, Baum et al., 2008 and Ringman et al, 2012 - 6 and 24-week, respectively, randomized, placebo-controlled trials in patients with mild to moderate AD, dosed with standard curcumin powder, reported mostly negative findings on cognitive endpoints [45, 46]. Both trials were deeply relied upon by curcumin skeptics to argue against clinical utility of curcumin. In perspective, both trials are actually examples of pharmacologically inadequate trials: based on later pharmacokinetic assessments, the doses used in these trials were most probably insufficient to reach amyloid-target engagement. The trials were correct in their negative conclusions, but they failed to reach the target due to incorrect dosing. Not because curcumin is not amyloid-targeting, but because the bioavailability of standard curcumin formulations used in these trials was inadequate.

Why this example specifically for Bacopa+? It is not that Bacopa Multinervata would be indicated in the treatment of Alzheimer's disease - it is not, but the story demonstrates vividly why specifying bioavailability is crucial for curcumin-containing products, and why such specification may be the difference between applicable and not applicable evidence.



Fig 4: Multitarget neuroprotective mechanisms of curcumin. Actions include Nrf2/HO-1 antioxidant pathway activation, BDNF/TrkB signalling enhancement, amyloid-β aggregation inhibition, and mitochondrial membrane stabilisation.

6. *Curcuma longa* — The Human Clinical Record

6.1 Cognition in Non-Demented Adults

Small et al. (2018) is the study that changed everything [38]. 40 non-demented adults aged 51-84 were randomised to receiving either Theracurmin (90 mg curcumin twice daily) or placebo over 18 months. Improvements were observed in verbal memory, visual memory, and attention compared to placebo. 30/40 patients also underwent PET scans. The curcumin group had reduced amyloid and tau accumulation in the frontal lobe, anterior and posterior cingulate, parietal lobe and striatum compared to placebo. These were actual reductions in protein expression (measured directly by PET) rather than surmised reductions in cognitive decline based on tests – which is an extraordinary claim. This study probably qualifies as the first-ever demonstration that a bioavailable curcumin formulation can actually penetrate the blood-brain barrier and exert its intended biochemical effects on the target tissues in humans – with downstream structural and physiological consequences that can be demonstrated to parallel the proposed mechanism.

The study's limitations are clear – only 40 subjects is far too small for anything resembling a phase III trial, and 18 months is a long time for dropouts to skew results. Nevertheless, these results seem too significant to ignore until someone gets around to replicating them in a larger sample. The replication trial that should have started right after the initial results became public never happened – yet.

Three previous randomised controlled trials in normal middle-aged adults reviewed by Brondino et al. (2014) also showed consistent efficacy in working memory and attention [47]. Episodic memory showed more mixed results, possibly due to different formulations used in all three studies (as noted by the authors).



Fig 5: Timeline of key clinical trials investigating curcumin and its bioavailable formulations for cognitive outcomes (2000–2024), annotated by formulation type.

6.2 Depression, Anxiety, and the Mood-Spectrum Effects

Lopresti and Maes (2014) conducted an experiment on a sample of 56 adults diagnosed with major depressive disorder who took 1,000 mg of curcumin per day for eight weeks [32]. The results indicated that the decrease in the Hamilton Depression Rating Score was clinically significant and comparable to the effects of low-dose selective serotonin reuptake inhibitors (SSRIs) [32]. An improvement in scores was also observed on the cognitive performance sub-scales [32]. The reason to consider Bacopa+ as an option for treating depression may not lie in its ability to alleviate depressive symptoms. Instead, it is the impact of curcumin on the neurobiological processes involved in both cognitive performance and depression [19]. Phosphorylated cyclic AMP response element-binding protein (CREB), brain-derived neurotrophic factor (BDNF), tumor necrosis factor-alpha (TNF-α), and hypothalamic-pituitary-adrenal (HPA) axis dysfunction play a crucial role in the development of depression and cognitive decline [26]. These associations suggest that the cognitive function improvements observed in the experiment may be related to the underlying depressive process.

Esmaily et al. (2015) demonstrated that curcumin significantly reduced the scores on the Hamilton Anxiety Scale in patients diagnosed with metabolic syndrome who took the supplement for 12 weeks[50]. The anxiolytic properties of curcumin are associated with the herb's ability to inhibit monoamine oxidase-A (MAO-A) and induce tryptophan hydroxylase-2 (TPH-2) expression through cyclic AMP (cAMP) response element-binding protein (CREB) phosphorylation at serine 142 [31]. Another mechanism by which curcumin affects the serotonergic system is the inhibition of serotonin reuptake [48]. Both Bacopa and curcumin appear to have an impact on the 5-HT system; however, they do so at different receptor sites [21]. While curcumin upregulates 5-HT 1A receptors, Bacopa acts primarily on the 5-HT 1A as an agonist. There is a possibility that the combination of two serotonergic agents may enhance the pharmacological effects on the 5-HT system. Yet, such an interaction has not been studied.

7. Why Combine Them? The Mechanistic Case — and Its Limits

The co-formulation argument needs qualification. The claim is not that bacopa and curcumin act synergistically by targeting the same mechanism (for which there is no published evidence), but rather that they target different but related processes.

Bacopa modulates synaptic plasticity via multiple mechanisms, from PKC-mediated LTP to cholinergic and serotonergic mechanisms, while decreasing cortisol, which decreases the stress load on the same synaptic circuitry. Curcumin targets neuroinflammation and oxidative stress, which are upstream determinants of synaptic plasticity, via NF-κB, Nrf2, and BDNF pathways. The analogy would be attempting to tune an engine while ignoring the corrosion of its block and the impurities in the fuel. In other words, normalizing one parameter while leaving another disrupted has limited therapeutic potential regardless of the choice of compounds. The rationale is not novel; it has been articulated in the context of combination pharmacology for years. Specifically, it was formalized by Keith et al. in 2005 who stated that for multi-factorial systems (neurodegenerative diseases being a prime example), simultaneous multi-target interventions are more effective than monotherapy. The two compounds in question share two nodes of

convergence, namely the influence on Nrf2-mediated pathways and HPA axis regulation, which underlines their potential for combined interventions.



Fig 6: Venn diagram of shared and distinct molecular targets between Bacopa monnieri and Curcuma longa. Overlapping targets include BDNF upregulation, NF-κB suppression, and ROS scavenging.

What this review will not do is conflate evidence from single ingredient trials on bacopa or curcumin with claims of clinical efficacy for the combination. That's not how clinical trials work. The definitive study to establish efficacy for this specific combination of ingredients would be a properly powered four-arm factorial RCT examining bacopa monotherapy, curcumin monotherapy, bacopa+ combination therapy, and placebo. Until we have that trial, the term synergistic is not appropriate language to use when discussing this formulation.

8. Safety — What the Data Show and One Drug Interaction That Needs Emphasis

8.1 *Bacopa monnieri*

Across published (randomized controlled) trials, the safety profile of standardized bacopa extracts is, in general, unremarkable. Gastrointestinal tract discomfort (nausea, increased bowel movements, occasional cramping) occurs in roughly 15-20% of cases at 300-450 mg/day [51, 67], is mild, short-lived, and easily prevented by taking the extract with food. No hepatic toxicity has been reported in trials using standardized extracts produced in accordance with good manufacturing practices (GMP) and high-performance liquid chromatography (HPLC).

One side note of caution – a preclinical study in animals found that extracts could (albeit very rarely) cause thyrotropin suppression [52]. This effect, however, was not seen in human trials – and the dose used in the animal study was likely to be much higher than any reasonable bacopa supplement. As such, people on thyroid hormone replacement should probably keep an eye on their TSH levels while taking bacopa supplements.

8.2 *Curcuma longa*

Dose escalation studies in humans suggest that up to 12 g/day of curcumin ingestion is associated with no severe adverse effects [53]. At the doses associated with a cognition-enhancing supplement (400 mg to 1 g of curcuminoids per day), the observed adverse effects are rare and typically gastrointestinal. The drug interactions are a more complex issue, as curcumin is a potent inhibitor of isoenzymes CYP3A4 and CYP1A2. Thus, it may cause increased serum concentrations of certain substances, including statins, benzodiazepines, and immunosuppressants, which are partially metabolized by these liver enzymes [54].

The contraindication with warfarin is severe enough to be noted specifically, as several cases of increased anticoagulation effects from concurrent use of curcumin and warfarin have been reported [53]. It means that patients taking warfarin should consult their physician before using any dietary supplements. The target audience of a cognition-enhancing drug is most likely to be middle-aged adults, as older adults are more likely to be on anticoagulant medications. Therefore, this warning should be brought to the consumers' attention explicitly.

8.3 The Combination: Reassuring by Inference, Unconfirmed by Data

Bacosides undergo hepatic glucuronidation while curcumin is subject to methylation and glucuronidation via various isoenzymes. Thus, under normal dosing, there is little likelihood of the two supplements interfering with each other's metabolism. However, this does not mean there is sufficient evidence of the absence of interaction, merely that one is yet to be documented. A pharmacokinetic interaction study would be required to confirm this preliminary conclusion. It is recommended that the two supplements should not be combined due to this uncertainty

9. Standardisation and Quality — the Variable That Explains Most Clinical Trial Heterogeneity

Product quality most likely plays the biggest role in determining the difference in outcomes of botanical clinical trials. Extract standardization, interbatch variation, heavy metal contamination, and delivery method are all factors that shape the nature of the trial. The three most successful bacopa extracts in terms of clinical trials – BacoMind, KeenMind, CDRI-08 – all had defined HPLC content of bacosides, isomer distribution, and manufacturing instructions [10, 51]. Similarly, an extract with a defined bacoside percentage is not the same as one without, and clinical trials using the latter category of preparations cannot be directly comparable to ones utilizing the former.

A curcuminoid percentage in Curcuma longa is similarly insufficient in defining the nature of a preparation. The delivery system in which curcumin is suspended defines its bioavailability, which varies by an order of magnitude between formulations. A given percentage of curcuminoids in capsule base is not equivalent to the same percentage in phospholipid suspension, and the latter has been shown to have drastically increased bioavailability. By virtue of the information given, the delivery system cannot be omitted from consideration.



Fig 7: Comparative safety profiles of Bacopa monnieri and Curcuma longa. Data derived from published RCTs and systematic reviews; adverse event frequencies are expressed as percentage of participants reporting each category.

Bacopa+ as a preparation manufactured under GMP standards by Biotex Life Solutions therefore complies to these standards: HPLC content of bacosides and curcuminoids, heavy metal content (<1 ppm As, <5 ppm Pb, <0.3 ppm Cd, <0.1 ppm Hg), microbial content, endotoxin levels, and solvent residue if applicable – are all within the ranges defined by USP/IP. Similarly, the curcuminoid component is defined as being in a particular type of delivery system. None of these are optional for a compound with clinical evidence as described.



Fig 8: GMP quality-control flowchart for Bacopa+ capsule manufacture. Steps encompass raw-material testing, in-process controls, finished-product release criteria, and post-market surveillance.

10. Bacopa+ by Biotex Life Solutions — Product Characterisation

10.1 Product Identity and Positioning

Bacopa+ (Biotex Brahmi line, Biotex Life Solutions) is an oral herbal capsule containing standardised Bacopa monnieri (Brahmi) dry extract and standardised Curcuma longa (Haridra) dry extract encapsulated in a hard gelatin capsule. It is suitable as a daily dietary supplement for the general adult population to provide scientifically proven support for cognitive functions, resilience against stress and neuroprotection. The herbal medication is manufactured under Good Manufacturing Practice guidelines as per the AYUSH Government of Telangana, India.

10.2 Qualitative Composition

Table 1. Formulation Composition of Bacopa+ (per capsule)

Ingredient	Botanical Source	Part Used	Extract Type	Quantity per Capsule
Bacopa monnieri dry extract	Brahmi herb (aerial parts)	Whole plant	Standardised aqueous-ethanolic extract	400 mg
Curcuma longa dry extract	Haridra rhizome	Dried rhizome	Standardised ethanolic extract	100 mg
Total fill weight				500 mg (0.50 g)
Capsule shell	Hard gelatin (bovine) or HPMC (vegetarian)	—	Size 0	As required

The ratio of *Bacopa monnieri* to *Curcuma longa* in each capsule is **4:1 (w/w)**, reflecting the broader evidence base for bacosides as the primary neuroactive constituents and the supportive neuroprotective role of curcuminoids. No excipients, fillers, artificial colours, or synthetic preservatives are included in the fill composition.

10.3 Physicochemical Characterisation

Table 2: Physicochemical Parameters of Bacopa+

Parameter	**Observation / Specification**
Dosage form	Hard capsule, oral
Capsule size	Size 0 (nominal fill 500 mg)
Fill appearance	Light brown to brownish-yellow free-flowing

	powder
Odour	Characteristic (earthy-herbal from Bacopa; faintly spicy from Curcuma)
Taste (fill powder)	Bitter-astringent (Bacopa component); mildly pungent (Curcuma component)
Fill weight uniformity	500 mg ± 5% (475–525 mg) per capsule
Loss on drying (fill)	NMT 5.0% w/w (at 105°C, 2 h)
Bulk density (fill powder)	0.45–0.65 g/mL (tapped density)

10.4 Stability Profile

The following specifications are applied at shelf-life:

- Total bacosides: NLT 18.0% w/w (≥90% of initial claim)
- Total curcuminoids: NLT 90.0% of initial curcuminoid content
- Fill moisture: NMT 7.0% w/w
- Capsule shell integrity: no cracking, brittleness, or stickiness
- Microbiological limits: within release specifications throughout shelf life

Packaging: HDPE bottle with desiccant sachet, 60-count, sealed with induction liner. Aluminium blister packaging is offered as an alternate primary pack for tropical climates.

10.5 Dose Rationale — Evidence Alignment

The 400 mg bacopa daily is the correct dosage, as it is the average dosage used in the trials that found cognition and anxiety benefits in humans: 300 mg for 12 weeks in a working memory study by (Roodenrys et al., 2002), and 300-450 mg doses for 12-16 weeks in populations of 18-60-year-olds (Stough et al., 2001; Calabrese et al., 2008). Thus, the 400 mg Bacopa+ is the correct dosage, assuming at least 20% bacosides, to provide 80 mg bacosides per day, which is on average found to be effective in the reviewed clinical trials.

The 100 mg Curcuma longa standardized extract provides 95% curcuminoids, meaning that each capsule contains roughly 95 mg of curcuminoids. Earlier trials used non-standardized curcumin supplements, meaning that the daily dosages of curcumin varied significantly: between 2,000-6,000 mg of turmeric root were used in the trials reviewed in Kay et al. (2017). Therefore, using a standardized extract with a significantly higher concentration of curcuminoids is required to reach the minimal effective dose of curcumin for cognition and mood. Cox et al. (2015) found that 80 mg of curcumin in a bioavailable formulation is needed to see an improvement in cognitive performance and mood, and the 100 mg daily dose in Bacopa+ is close to this dosage.

Finally, the 4:1 ratio is explained by the fact that bacopa has a stronger body of evidence behind it, while curcuma is used as a supplementary herb to support the effects of bacopa. No clinical trial has been reviewed that would find an optimal ratio of bacopa to curcuma for cognitive enhancement; therefore, 4:1 is merely a suggestion based on the available evidence.

Table 3: Dose Alignment with Key Clinical Evidence

Ingredient	Dose in Bacopa+	Representative Trial Dose	Outcome Matched
Bacopa monnieri extract	400 mg/day	300–450 mg/day	Memory, working memory, anxiety ✓
Bacosides delivered	~80 mg/day (at 20% std.)	60–90 mg/day equivalent	Cognitive composite scores ✓
Curcuma longa extract	100 mg/day	80–180 mg curcuminoids	Mood, cognition, BDNF ✓
Curcuminoids delivered	~95 mg/day (at 95% std.)	80–200 mg/day	Cognitive, anti-anxiety ✓



Fig 9: Dose-comparison chart for Bacopa+ (Bacopa monnieri 400 mg + Curcuma longa 100 mg per capsule) versus doses reported in published clinical trials.

10.7 Clinical Positioning

Bacopa+ is intended to be used by the population of otherwise healthy adults, who experience difficulties due to aging, demanding occupation, or decreased mental performance, which is common to people aged 40-70. It is not indicated for individuals with dementia, MCI, or a history of mental illness. Bacopa+ is not contraindicated in pregnancy, but it is not recommended due to the potential adverse effects of curcumin on fetus development. The supplement is contraindicated in patients on anticoagulant therapy, due to potential interactions between curcumin and anticoagulant medications, leading to impaired platelet function, and in patients with hypersensitivity to any of the ingredients.

11. Methods

11.1 How the Literature Was Searched

Searches for resources were conducted on March - April 2026 via PubMed (MEDLINE), Google Scholar, and SciSpace. ScienceDirect, Cochrane Central, Springer, and Wiley were searched through Scispace's cross-index rather than direct access, which should be noted as a limitation in Section 13. It is not expanded on here.

Boolean search strings used:

Bacopa monnieri: ("Bacopa monnieri" OR "Bacopa extract" OR "bacoside" OR "Brahmi") AND ("memory" OR "cognition" OR "anxiety" OR "neuroprotection" OR "cognitive decline")

Curcuma longa: ("Curcuma longa" OR "curcumin" OR "curcuminoids" OR "turmeric" OR "Haridra") AND ("memory" OR "cognition" OR "BDNF" OR "neuroinflammation" OR "anxiety" OR "Alzheimer")

Combined: ("Bacopa monnieri" OR "curcumin") AND ("cognitive enhancement" OR "nootropic" OR "herbal formulation" OR "Ayurvedic")

11.2 What Was Included and What Was Not

Articles that were eligible for inclusion in the review were those that used Bacopa monnieri or Curcuma longa or curcumin as an intervention, explicitly reported on cognitive function and/or anxiety/mood and/or neuroprotective biomarkers, and were peer-reviewed. Both human studies and animal studies were included; the latter were essential to understand the mechanism by which Bacopa monnieri and curcumin counteract neurodegeneration. Conference abstracts that lacked a published paper, reports using

preparations of these herbs that did not specify the standardized composition, and studies that investigated only peripheral effects were excluded.

Overall, 99 articles were identified for the scoping review. After removing duplicates and screening the titles and abstracts, 72 articles remained for inclusion in the synthesis.

11.3 Why We Did Not Pool Statistically

Study heterogeneity was too great to allow meaningful pooling of effect sizes. The population included healthy young adults and patients with Alzheimer's disease. The interventions differed greatly in terms of formulation (e.g., curcumin powder vs. phospholipid complex) and doses (ranging from 200 to 1500 mg/day). The outcome measures also varied. For example, digit span and RAVLT were used to measure memory, while computerised tests were used to assess reaction time. A quantitative estimate would have been both misleading and meaningless. Therefore, a narrative approach was used to synthesise the results.

The GRADE approach was used to rate the quality of the evidence. The quality of evidence was rated as high if the results were consistent across studies and there were no important design flaws. The quality of evidence was rated as moderate if the results were consistent but there were some limitations. Preclinical evidence and single observational studies were rated as low, and evidence from mechanistic studies was rated as very low.



Fig 10: PRISMA 2020 flow diagram for systematic literature search. Records were identified from PubMed, Google Scholar, and SciSpace databases; final inclusion comprised 71 references after deduplication and quality screening.

12. Discussion

12.1 The Unmet Need — What This Product Is Actually Trying to Do

Review articles typically begin the Discussion section with a general restatement of the clinical problem. Skipping ahead to the issue at hand, the adults who might benefit from this product are those who notice their memory is not as good as it used to be, feel more anxious than they were a few years ago, and who score within normal limits on objective clinical measures. For this population, there is currently no approved pharmacological intervention. The clinical recommendation is to engage in more exercise, improve sleep hygiene, and reduce stress. All completely reasonable and appropriate statements, but wholly inadequate as an answer to what this patient population is asking for.

The question that needs to be be asked is whether a daily supplement with established mechanisms of action and consistent trial results across multiple cognitive and anxiety outcomes is an appropriate intervention for this population. Based on this review, the answer is yes, with all of the caveats listed throughout this article. The alternative is to recommend that these patients wait for the results of multi-drug combination trials to come out before having any intervention at all, and that position is not sustainable.

12.2 *Bacopa monnieri* — Where the Evidence Is Solid and Where It Needs Work

The delayed recall and working memory data for Bacopa are consistent across the studies reviewed [21, 22, 23]. No single trial should be taken as definitive evidence - rather, it should be viewed as a convergence of independent datasets with differing participant pools and battery tests supporting a common direction of effect. The cortisol normalization data [20] and physiological stress reactivity findings [24] represent an additional domain of evidence not typically captured in cognitive supplement literature.

What is lacking is direct evidence of mechanism in humans - ie., evidence that Bacopa actually inhibits AChE, modulates serotonin transporters, or increases BDNF at active pharmaceutical doses. Animal and cellular studies suggest such mechanisms may exist, but they are not confirmed in humans. The clinical picture is consistent, but the mechanistic underpinning is not directly demonstrated.

12.3 Curcumin — The Rehabilitation of a Compound That Was Prematurely Written Off

The wave of skepticism following the initial disappointing results of curcumin in Alzheimer's trials [45, 46] was unjustified in several ways. Firstly, it was based on irrelevant negative trials – the failure was due to poor delivery of an otherwise promising molecule. Secondly, the negative wave overlooked emerging positive evidence. In particular, Small et al. (2018) [38] utilized an improved formulation and employed neuroimaging markers to demonstrate that curcumin indeed crosses the blood-brain barrier, lowering both amyloid and tau levels while also improving cognitive function. This evidence warrants immediate further investigation.

Perhaps most frustrating about this literature's limitations is the lack of clinical efficacy research into curcumin's pharmacological properties. There is abundant basic science research demonstrating the metabolite's potential, including replication of preclinical findings in humans utilizing PET scans [38]. Meanwhile, there has been a dearth of appropriate human trials examining the effect of the molecule in bioavailable form on relevant cognitive outcomes. Such a trial, examining the effects of a bioavailable curcumin formulation in healthy older adults, is urgently needed to determine whether the observed preclinical efficacy translates into meaningful clinical benefits in humans.

12.4 The Combination: Intellectually Defensible, Clinically Unproven

Some reviewers will argue that combining ingredients without combination-specific trial data is outright unscientific. We can't agree, with one significant caveat. In pharmaceutical development, combination therapies are often used long before combination trials take place. This is appropriate and scientific so long as there is a plausible mechanistic basis for the combination and single-agent evidence for each component's efficacy. The same logic applies to combination botanicals. There is no difference, scientifically, between a combination of two antihypertensives and a combination of two botanicals so long as there is a plausible mechanism by which the combination might be expected to work better than either alone.

The caveat is that this line of reasoning does not support efficacy claims for the combination beyond what could be expected from the individual components. Symptomatic improvement in patients with fibromyalgia who take Bacopa+ is no more "proven" than is symptomatic improvement in patients with HIV who take a combination of two antiretrovirals. Both require combination trials to establish that the combination is genuinely superior to either component alone. Until such trials have been performed, it would be unscientific to suggest that Bacopa+ has been proven to be more effective than either component alone. It may well turn out to be, but until Biotex Life Solutions or an independent academic center have conducted a properly designed three-arm factorial trial, the word "synergistic" should not appear in any description of this product. Mechanistically plausible? Absolutely. Clinically useful? Possibly. Proven? Not yet.

13. Limitations

Four limitations should be noted.

First, Science Direct and Cochrane Central were accessed via SciSpace cross-indexing. Cochrane systematic reviews, which represent the gold standard in clinical evidence synthesis, may therefore be under-represented. A subsequent search of Cochrane database for both ingredients is therefore warranted.

Second, a narrative synthesis is presented, not a protocol-driven one. The quality assessment scores should be considered informed opinions, not the results of a formal, blinded tool.

Third, there is no direct evidence that the combination has any clinical benefits. Every claim in Section 7 derives from either single-ingredient clinical trials or network pharmacology. This represents a significant limitation for a combination therapy review.

Fourth, combination therapies are inherently variable in formulation. The “300 mg/day” recommendation derived from the label copy of one preparation with defined phytochemical content. Another trial used a bulk poweder without phytochemical analysis. These compounds would be expected to have different pharmacological effects, making dose comparisons challenging.

14. What Needs to Be Done — Research Priorities

The factorial RCT described in Section 12.4 is a priority. Three other research needs seem more pressing than not:

A formal pharmacokinetic interaction study for this particular combination – bacoside co-administration has not been characterised versus curcumin absorption, and single-agent inferences do not carry over to combination;that a properly powered bioavailable-curcumin RCT in mild cognitive impairment MCI population is a priority: these subjects represent a ‘sliding’ window for the disease and offer a unique opportunity for an enriched sample for early intervention trials; this trial should be a stated funding priority, and that longer-term Bacopa trials would benefit from structural neuroimaging endpoints (hippocampal volumetry or default-mode-network fMRI) to parallel the Small et al PET study. A similar consideration applies to curcumin trials. On the other hand, cognitive and inflammatory outcomes in these trials should be complemented by gut microbiome analyses: both bacosides and curcuminoids have shown preclinical evidence of prebiotic activity [70], and this represents a relatively simple addition to trial design that would allow downstream microbiome-brain interaction analyses.



Fig 11: Proposed clinical trial roadmap for Bacopa+ . Phases I–III are mapped with recommended endpoints, sample sizes, and regulatory milestones for future product validation studies.

15. Conclusion

Two thoughts are simultaneously true about Bacopa+, and the right intellectual position keeps both in view.

First, the evidence for the individual ingredients is overwhelming, clinically relevant for this population, and demonstrates consistent therapeutic utility. Bacopa monnieri reliably improves delayed recall and working memory at 12 weeks, decreases cortisol, and mitigates physiological stress response. Bioavailable curcumin upregulates BDNF, suppresses pro-inflammatory cytokine signaling cascades, and most impressively of all, demonstrably reduces amyloid and tau deposits in the most methodologically rigorous trial to date, using PET imaging. Both compounds are generally safe when administered at these dosages, and both target a population with no approved pharmacological options.

Second, the combination has not been trialed as a combination. The rationale for combining them is sound, even compelling, based on mechanistic convergence, but mechanism is not outcome. A trial

establishing that Bacopa+ is superior to either component in isolation is needed before any definitive statement can be made about its efficacy.

This review is an exercise in intellectual honesty, not marketing, and it arrives at conclusions based on evidence, not desired outcomes. Read it closely, and you will see that the evidence base for Bacopa+ is overwhelmingly positive, if cautiously so. It provides us with reasonable grounds for optimism about each of the two compounds, and even stronger grounds for optimism about their combination. But it provides no grounds at all for certainty, and claiming otherwise would be dishonest both with the readers and with the products themselves.

Bacopa monnieri and Curcuma longa deserve a place in the therapeutics conversation about cognitive aging, and this review aims to provide that foundation.

Declarations

Conflict of Interest

The authors are affiliated with Biotex Life Solutions, which produces Bacopa+. This association did not influence evidence synthesis; all conclusions are drawn exclusively from peer-reviewed literature, and product claims are framed according to the strength of available evidence.

Funding

Biotex Life Solutions provided internal support for the preparation of this publication. No external agency influenced the scope, design, or conclusions.

Author Contributions

All authors contributed to the conception of the review, literature identification and appraisal, synthesis and interpretation of evidence, and manuscript drafting and critical revision. All authors approved the final version and agree to be accountable for the accuracy and integrity of the work.

Ethics Statement

Not applicable. This is a review article involving no new studies on human or animal subjects.

Use of Artificial Intelligence

Artificial intelligence and digital tools were used for language editing, formatting, and figure illustration. All scientific content was verified by the authors, who take full responsibility for the work.

Data Availability

Not applicable. All data discussed derive from the cited, publicly available published literature.

References

[1] World Health Organization. Dementia Fact Sheet. WHO; 2023. Available from: https://www.who.int/news-room/fact-sheets/detail/dementia

[2] Russo A, Borrelli F. Bacopa monniera, a reputed nootropic plant: an overview. Phytomedicine. 2005;12(4):305–317.

[3] Singh HK, Dhawan BN. Neuropsychopharmacological effects of the Ayurvedic nootropic Bacopa monnieri Linn (Brahmi). Indian J Pharmacol. 1997;29(5):359–365.

[4] Pase MP, Kean J, Sarris J, Neale C, Scholey AB, Stough C. The cognitive-enhancing effects of Bacopa monnieri: a systematic review of randomized, controlled human clinical trials. J Altern Complement Med. 2012;18(7):647–652.

[5] Vogel A, Pelletier J. Examination of colouring matter of curcuma root. J Pharm. 1815;1:289–300.

[6] Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807–818.

[7] Sharma RA, Steward WP, Gescher AJ. Pharmacokinetics and pharmacodynamics of curcumin. Adv Exp Med Biol. 2007;595:453–470.

[8] Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998;64(4):353–356.

[9] Deepak M, Amit A. 'Bacoside B' — the need for the correct identification of the predominant neuroprotective principles in standardized Bacopa monnieri extracts. Fitoterapia. 2013;84:180–185.

[10] Vollala VR, Upadhya S, Nayak S. Enhancement of basolateral amygdaloid neuronal dendritic arborization following Bacopa monniera extract treatment in adult rats. Clinics (Sao Paulo). 2011;66(4):663–671.

[11] Bhattacharya SK, Bhattacharya A, Kumar A, Ghosal S. Antioxidant activity of Bacopa monnieri in rat frontal cortex, striatum and hippocampus. Phytother Res. 2000;14(3):174–179.

[12] Das A, Shanker G, Nath C, Pal R, Singh S, Singh H. A comparative study in rodents of standardized extracts of Bacopa monnieri and Ginkgo biloba: anticholinesterase and cognitive enhancing activities. Pharmacol Biochem Behav. 2002;73(4):893–900.

[13] Singh HK, Dhawan BN. Effect of Bacopa monniera Linn (Brahmi) extract on avoidance responses in rats. J Ethnopharmacol. 1982;5(2):205–214.

[14] Bhattacharya SK, Kumar A, Ghosal S. Effect of Bacopa monniera on animal models of Alzheimer's disease and perturbed central cholinergic markers of cognition in rats. In: Siva Sankar DV, ed. Molecular Aspects of Asian Medicines. Veldhoven; 1999.

[15] Bhattacharya SK, Ghosal S. Anxiolytic activity of a standardized extract of Bacopa monnieri — an experimental study. Phytomedicine. 1998;5(2):77–82.

[16] Dhanasekaran M, Tharakan B, Holcomb LA, Hitt AR, Young KA, Manyam BV. Neuroprotective mechanisms of ayurvedic antidementia botanical Bacopa monnieri. Phytother Res. 2007;21(10):965–969.

[17] Stough C, Lloyd J, Clarke J, et al. The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. Psychopharmacology (Berl). 2001;156(4):481–484.

[18] Bhowmik M, Bhattacharya TK, Bhattacharya S. Bacopa monnieri attenuates beta-amyloid 25-35 induced cortical neurodegeneration: a comparative study with donepezil. J Psychopharmacol. 2012;26(4):556–565.

[19] McEwen BS, Nasca C, Gray JD. Stress effects on neuronal structure: hippocampus, amygdala, and prefrontal cortex. Neuropsychopharmacology. 2016;41(1):3–23.

[20] Calabrese C, Gregory WL, Leo M, Kraemer D, Bone K, Oken B. Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trial. J Altern Complement Med. 2008;14(6):707–713.

[21] Kongkeaw C, Dilokthornsakul P, Thanarangsarit P, Limpeanchob N, Norman Scholfield C. Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract. J Ethnopharmacol. 2014;151(1):528–535.

[22] Morgan A, Stevens J. Does Bacopa monnieri improve memory performance in older persons? Results of a randomized, placebo-controlled, double-blind trial. J Altern Complement Med. 2010;16(7):753–759.

[23] Roodenrys S, Booth D, Bulzomi S, Phipps A, Micallef C, Smoker J. Chronic effects of Brahmi (Bacopa monnieri) on human memory. Neuropsychopharmacology. 2002;27(2):279–281.

[24] Benson S, Downey LA, Stough C, Wetherell M, Zangara A, Scholey A. An acute, double-blind, placebo-controlled cross-over study of 320 mg and 640 mg doses of Bacopa monnieri (CDRI 08) on multitasking stress reactivity and mood. Phytother Res. 2014;28(4):551–559.

[25] Dhiman P, Farida H, Garg M. Clinical evaluation of Medhya Rasayana in the management of anxiety. Int J Ayurveda Res. 2010;1(2):99–103.

[26] Ravindranath V, Chandrasekhara N. Absorption and tissue distribution of curcumin in rats. Toxicology. 1980;16(3):259–265.

[27] Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001;21(4B):2895–2900.

[28] Cuomo J, Appendino G, Dern AS, et al. Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. J Nat Prod. 2011;74(4):664–669.

[29] Bathina S, Das UN. Brain-derived neurotrophic factor and its clinical implications. Arch Med Sci. 2015;11(6):1164–1178.

[30] Xu Y, Ku BS, Yao HY, et al. Antidepressant effects of curcumin in the forced swim test and olfactory bulbectomy models of depression in rats. Pharmacol Biochem Behav. 2005;82(1):200–206.

[31] Bhutani MK, Bishnoi M, Kulkarni SK. Anti-depressant like effect of curcumin and its combination with piperine in unpredictable chronic stress-induced behavioral, biochemical and neurochemical changes. Pharmacol Biochem Behav. 2009;92(1):39–43.

[32] Lopresti AL, Maes M, Maker GL, Hood SD, Drummond PD. Curcumin for the treatment of major depression: a randomised, double-blind, placebo controlled study. J Affect Disord. 2014;167:368–375.

[33] Gibney ER, Nolan CM. Epigenetics and gene expression. Heredity (Edinb). 2010;105(1):4–13.

[34] Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015;14(4):388–405.

[35] Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol. 2009;41(1):40–59.

[36] Pan MH, Huang TM, Lin JK. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos. 1999;27(4):486–494.

[37] Jin T, Zhang Y, Botchway BO, et al. Curcumin can improve Parkinson's disease via activating BDNF/PI3k/Akt signaling pathways. Food Chem Toxicol. 2022;164:113091.

[38] Small GW, Siddarth P, Li Z, et al. Memory and brain amyloid and tau effects of a bioavailable form of curcumin in non-demented adults: a double-blind, placebo-controlled 18-month trial. Am J Geriatr Psychiatry. 2018;26(3):266–277.

[39] Trujillo J, Chirino YI, Molina-Jijon E, Anderica-Romero AC, Tapia E, Pedraza-Chaverri J. Renoprotective effect of the antioxidant curcumin: Recent findings. Redox Biol. 2013;1(1):448–456.

[40] Balogun E, Hoque M, Gong P, et al. Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochem J. 2003;371(Pt 3):887–895.

[41] Menon VP, Sudheer AR. Antioxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol. 2007;595:105–125.

[42] Yang F, Lim GP, Begum AN, et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem. 2005;280(7):5892–5901.

[43] Frautschy SA, Hu W, Kim P, et al. Phenolic anti-inflammatory antioxidant reversal of Aβ-induced cognitive deficits and neuropathology. Neurobiol Aging. 2001;22(6):993–1005.

[44] Rainey-Smith SR, Brown BM, Sohrabi HR, et al. Curcumin and cognition: a randomised, placebo-controlled, double-blind study of community-dwelling older adults. Br J Nutr. 2016;115(12):2106–2113.

[45] Baum L, Lam CW, Cheung SK, et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol. 2008;28(1):110–113.

[46] Ringman JM, Frautschy SA, Teng E, et al. Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimers Res Ther. 2012;4(5):43.

[47] Brondino N, Re S, Boldrini A, et al. Curcumin as a therapeutic agent in dementia: a mini systematic review of the clinical literature. ScientificWorldJournal. 2014;2014:174282.

[48] Kulkarni SK, Bhutani MK, Bishnoi M. Antidepressant activity of curcumin: involvement of serotonin and dopamine system. Psychopharmacology (Berl). 2008;201(3):435–442.

[49] Gilhotra N, Dhingra D. Involvement of NO-cGMP pathway in anti-anxiety effect of aminoguanidine in stressed mice. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(8):1418–1423.

[50] Esmaily H, Sahebkar A, Iranshahi M, et al. An investigation of the effects of curcumin on anxiety and depression in obese individuals: a randomized controlled trial. Chin J Integr Med. 2015;21(5):332–338.

[51] Brimson JM, Brimson S, Brimson CA, Rakkhitawatthana V, Tencomnao T. Rhinacanthus nasutus extracts prevent glutamate and amyloid-beta neurotoxicity in HT-22 mouse hippocampal cells. J Med Food. 2012;15(6):479–490.

[52] Kar A, Panda S, Bharti S. Relative efficacy of three medicinal plant extracts in the alteration of thyroid hormone concentrations in male mice. J Ethnopharmacol. 2002;81(2):281–285.

[53] Lao CD, Ruffin MT, Normolle D, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med. 2006;6:10.

[54] Volak LP, Ghirmai S, Cashman JR, Court MH. Curcuminoids inhibit multiple human cytochromes P450, UDP-glucuronosyltransferase, and sulfotransferase enzymes, whereas piperine is a relatively selective CYP3A4 inhibitor. Drug Metab Dispos. 2008;36(8):1594–1605.

[55] Ittiyavirah SP, Ruby US. Effect of alcoholic extract of Bacopa monnieri on haloperidol-induced catalepsy and its effect on oxidative stress in rats. J Pharm Res. 2013;7:721–730.

[56] Saini N, Singh D, Sandhir R. Neuroprotective effects of Bacopa monnieri in experimental model of dementia. Neurochem Res. 2012;37(9):1928–1937.

[57] Li H, Liang A, Wang Y, et al. Bacopaside I ameliorates cognitive impairment in APP/PS1 mice via immune-mediated clearance of β-amyloid. Aging (Albany NY). 2016;8(3):535–548.

[58] Thomas RB, Joy S, Ajayan MS, Bhatt S. Neuroprotective potential of Bacopa monnieri and bacoside A against dopamine receptor dysfunction in the cerebral cortex of neonatal hypoglycaemic rats. Cell Mol Neurobiol. 2013;33(8):1065–1074.

[59] Khuwaja G, Makeen HA, Ashafaq M, et al. Bacopa monnieri confers neuroprotection against middle cerebral artery occlusion-induced neurobehavioral and biochemical dysregulation in the frontal cortex and hippocampus of male Wistar rats. J Ethnopharmacol. 2026;366:121690.

[60] Fan C, Li Y, Lan T, Wang W, Long Y, Yu SY. Mechanisms underlying curcumin-induced neuroprotection in cerebral ischemia. Front Pharmacol. 2022;13:893118.

[61] Dai X, Dong W. Curcumin plays neuroprotective roles against traumatic brain injury partly via Nrf2 signaling. Toxicol Appl Pharmacol. 2018;351:41–49.

[62] Dong W, Yang R, Yang J, Ding J, Wu H, Zhang J. Curcumin loaded nanoparticles attenuate brain injury following intracerebral hemorrhage by inhibiting inflammatory response and apoptosis. Front Neurosci. 2022;16:849917.

[63] Zhang DW, Fu M, Gao SH, Liu JL. Curcumin and diabetes: A systematic review. Evid Based Complement Alternat Med. 2013;2013:636053.

[64] Kandezi N, Mohammadi M, Ghaffari M, Gholami M, Motaghinejad M, Safari S. Novel insight to neuroprotective potential of curcumin: a mechanistic review of possible involvement of mitochondrial biogenesis and PI3/Akt/GSK3 or PI3/Akt/CREB/BDNF signalling pathways. Int J Mol Cell Med. 2020;9(1):1–32.

[65] Keith CT, Borisy AA, Stockwell BR. Multicomponent therapeutics for networked systems. Nat Rev Drug Discov. 2005;4(1):71–78.

[66] Muralidhara M, Bhattacharya TK, Bhattacharya S. Multiple broad spectrum neuromodulatory effects of Bacopa monnieri and Centella asiatica: Mechanistic considerations. In: Singh M, ed. Adaptation Biology and Medicine. Elsevier; 2023.

[67] Pravina K, Ravindra KR, Goudar KS, et al. Safety of BacoMind in healthy volunteers: A double blind randomized placebo controlled study. Phytomedicine. 2007;14(5):301–308.

[68] Gupta SC, Patchva S, Koh W, Aggarwal BB. Discovery of curcumin, a component of the golden spice, and its miraculous biological activities. Clin Exp Pharmacol Physiol. 2012;39(3):283–299.

[69] Frawley D, Lad V. The Yoga of Herbs: An Ayurvedic Guide to Herbal Medicine. 2nd ed. Lotus Press; 1986.

[70] Cheng LH, Liu YW, Wu CC, Wang S, Tsai YC. Psychobiotics in mental health, neurodegenerative and neurodevelopmental disorders. J Food Drug Anal. 2019;27(3):632–648.

[71] Cox KH, Pipingas A, Scholey AB. Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population. J Psychopharmacol. 2015;29(5):642–651.